Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YKP3089 adjunctive therapy dose-response trial in partial-onset seizures
2013-001858-10Phase 2Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cenobamate in epilepsy (3 arms), sponsored by SK Life Science, Inc. Primary endpoint: Percent reduction in seizure frequency. Started Aug 2013; status: completed.
02
Drugs
cenobamate
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2013-001858-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001858-10.